GILEAD SCIENCES, INC. is 23.5x more valuable than Kymera Therapeutics, Inc. by market capitalization ($151.05 B vs $6.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | GILD |
|---|---|---|
| Market cap | $6.44 B | $151.05 B |
| US-listed rank | #1211 | #99 |
| Revenue (latest FY) | $39.21M | $29.44B |
| Net income (latest FY) | $311.35M | $8.51B |
| Net margin | 794.0% | 28.9% |
| P/E (trailing FY) | 20.7 | 17.7 |
| SEC filings | 575 | 981 |
GILEAD SCIENCES, INC. is 23.5x more valuable than Kymera Therapeutics, Inc. by market capitalization ($151.05 B vs $6.44 B).
In their latest fiscal years, Kymera Therapeutics, Inc. reported $39.21M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Kymera Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.